The global tuberculosis testing market size was valued at US$ 3.02 Bn in 2020 and is anticipated to expand at a CAGR of 4.5% from 2021 to 2027. Tuberculosis is a bacterial infectious disease caused by Mycobacterium tuberculosis (MTB). Tuberculosis spreads through air and direct contact with the infected sputum. Tuberculosis usually affects lungs. But it can affect any other parts of the body. Tuberculosis patient generally experiences symptoms such as cough, chills, fever, fatigue, loss of weight and others. TB infecting bones can lead to joint destruction or spinal pain. The most common diagnostic test used for TB is skin test, but it is not fully accurate. There are many tuberculosis tests are available such as blood test, sputum tests, and Chest X-rays. The tuberculosis testing market is consolidated with the presence of strong market key players involving in development and marketing of the tuberculosis tests. Companies adopting the strategies such as mergers and acquisitions to strengthen their market position and expand their global reach. For instance, in October 2017, Abbot Laboratories has acquired Alere Inc., to become a leading market player in point of care testing and advance its geographical reach. Furthermore, market layers also developing new testing technologies and novel products to increase their market share. For instance, in Feb 2012, Quanterix Corporation collaborated with the Forsyth Institute and Beth Israel Deaconess Medical Center (BIDMC) to develop the fast and simple test for accurate diagnosis of tuberculosis.